VALUENCE
Valuence Japan Inc. (Tokyo; Susumu Muguruma, representative director and president), a member of the Valuence Group (TOKYO:9270), announced on July 1, the launch of the official version of its winning bid market price chart, available by subscription. The official version of the service has been upgraded and comes with new, useful features. Star Buyers Auction is a luxury brand goods auction service operated by Valuence Japan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210716005104/en/
New Features and Upgrades Reflect Partner Input
The Valuence Japan-operated Star Buyers Auction is a pre-owned luxury branded goods B2B auction and the main sales channel of the Valuence Group. Since the launch of Star Buyers Auction, the service has continued to grow in scale, adding new categories and offering new services, including online global auctions. In February 2021, Valuence Japan introduced a beta version of a market price chart subscription service for use by partners around the world. This service displays global market prices (actual winning auction bids) for a variety of goods. The company received abundant and valuable feedback from its partners regarding bidding and consignment sales, at the same time attracting an increasing number of new subscribers.
Valuence Japan added new functions to the Star Buyers Auction market price chart subscription service, incorporating feedback from partners. The company released the official upgraded version of the service on July 1. At the same time, the company will continue to look at upgrading the service based on feedback, striving to create a global reuse platform serving as an indispensable part of the purchasing and selling markets.
Official Version and Upgrades
The official version of the market price chart service now allows users to enter multiple search terms, including brand and model names. This powerful upgrade reduces time spent in search for specific products. Users may also conduct searches by transaction date range, providing a narrower view of the vast amount of transaction data available. The search results screen now displays accessories, prices, and transaction dates in either ascending or descending order. Here, users will be able to sort through information, including accessories, price ranges, and other data for multiple products. Search results draw on the more than 25,000 items sold every auction, demonstrating the vast amount of valuable market data accumulated by Star Buyers Auction.
Valuence Japan is confident that the upgraded version of this service will deliver the type of market price information needed and used by the B2B auction partners.
Star Buyers Auction Overview
A luxury brand goods auction for reuse business dealers, launched in April 2013. In April 2020, auctions were migrated to a fully online format, listing a constantly stable stream of luxury items both in quantity and quality. Listings primarily focus on watches, bags, and brand jewelry procured by the Valuence Group. Auctions are held twice monthly. Market price chart subscription service is also available for 11,000 yen per month.
Official Site: https://biz.starbuyers-global-auction.com/en/
Youtube: https://youtu.be/efUtXrO9JkE
View source version on businesswire.com: https://www.businesswire.com/news/home/20210716005104/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom